Data Shows Minimally Invasive Treatment Provides Rapid Symptom Relief, Allowing Men to Return to Daily Activities Quickly WAYNE, Pa.— June 22,... Read More
Data Presented at American Urological Association 2020 Virtual Experience Highlight Benefits and Superior Sexual Function* Preservation of the Minimally Invasive Treatment for Patients with Enlarged Prostate WAYNE,... Read More
The Teleflex mission to improve the health and quality of people’s lives has taken on a new meaning during the COVID‑19 pandemic.... Read More
January 7, 2020 Minimally Invasive Procedure Now Available to Hundreds of Thousands More Men with Enlarged Prostate, Providing Safe and Effective Symptom Relief.... Read More
Minimally Invasive Treatment Options for BPH Remain Critical Due to Shortcomings of Surgery and Medication WAYNE, Pa. –Sept. 16, 2019 – Teleflex Incorporated (NYSE: TFX) today announced the publication of an article showcasing the effectiveness and overall benefits of the minimally invasive UroLift® System treatment for patients with benign prostatic hyperplasia (BPH).... Read More
Results from Multi-Center Study Support the Application of Minimally Invasive Treatment for Broader BPH Population WAYNE, Pa. – July 9,... Read More
The UroLift® System for the treatment of Benign Prostatic Hyperplasia (BPH) was the subject of three presentations at the Glasgow, Scotland-held urology event: a study men with acute urinary retention;... Read More
PLEASANTON, Calif. – December 14, 2018 – NeoTract, a wholly owned subsidiary of Teleflex Incorporated (NYSE:TFX) focused on addressing unmet needs in the field of urology,... Read More
A new Government scheme announced today selects the UroLift® System as one of seven innovations across all specialisms that are the most transformative for NHS patients ... Read More
WAYNE, PA – June 08, 2018 – NeoTract, a wholly owned subsidiary of Teleflex Incorporated (NYSE:TFX) focused on addressing unmet needs in the field of urology,... Read More
US
AU
UK